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Conclusions: At the moment the Partial Breast Irradiation is 
a procedure still under investigation as it is encumbered by 
high risk of local relapse as compared with external beam (OS 
is similar), as confirmed also by our study. Nevertheless it 
gained a great appeal among women and the IORT can be 
offered to accurately selected pts.  
   
PO-0684   
Morbidity after regional nodes radiotherapy in early breast 
cancer patients having axillary lymph node dissection 
H. Nielsen1, R. Friis1, S. Linnet2, B. Offersen1 
1Aarhus University Hospital, Department of Oncology, Aarhus 
C, Denmark  
2Herning Hospital, Department of Oncology, Herning, 
Denmark  
 
Purpose/Objective: Axillary lymph node dissection (ALND) 
and adjuvant radiotherapy (RT) in breast cancer is associated 
with a risk of severe morbidity including lymphoedema, 
impaired function of the arm and chronic pain/sensory 
disability. The aim of this study was to evaluate the 
morbidity in two groups of heavily treated adjuvant breast 
cancer patients, differing only regarding inclusion or not of 
regional nodes in the RT volume.  
Materials and Methods: 347 patients consecutively operated 
from 2007-2012 with breast conservative surgery (BCS) and 
ALND (>= 3 micro- or macrometastases in sentinel node (SN) 
or SN not identified). All patients received adjuvant taxane 
based chemotherapy and if indicated, trastuzumab and 
endocrine treatment. The RT consisted of whole breast 
irradiation (WBI) to patients with pN0 and pN1mi disease and 
loco-regional RT in case of >= pN1 disease. The dose was in 
all patients 50 Gy in 25 fx. Only patients without recurrence 
were eligible for the study. They were invited to participate 
in a cross-sectional study regarding evaluation of objective 
physical impairments, and filling out a questionnaire 
regarding morbidity.  
Results: 277 patients participated. Of these, 185 patients 
(>=pN1), median 15 removed axillary nodes, received loco-
regional RT, median follow up 3.3 years, while 92 patients 
(pN0, pN1mi), median 16 removed axillary nodes, received 
WBI, median follow up 4.3 years. 
Circumferential ipsilateral arm difference of >= 2 cm of 
upper and/or lower arm was seen in 18% after loco-regional 
RT and in 16% after WBI (p=0.67). An increase of >= 10 % in 
ipsilateral upper and/or lower arm circumference was seen in 
8% (loco-regional RT) vs 3% (WBI) (p=0.12) and if this was 
combined with weekly use of an arm sleeve these numbers 
were 19% (loco-regional RT) versus 15% (WBI) (p=0.39). Self 
reported lymphoedema of ipsilateral upper/lower arm was 
found in 44%/33% (loco-regional RT) and in 40%/29% after WBI 
(p=NS).  
Severe impairments of shoulder function with abduction to 
120° or less was 3% after both loco-regional RT and WBI and 
severe impairments of shoulder flexion to 120° or less were 
1% and 2%, respectively. In the contralateral arm severe 
reduction of abduction/flexion was seen in 0.7%. No 
differences in self reported physical impairment, pain or 
sensory disturbances were seen between the two groups. 
Conclusions: Clinical lymphoedema is seen in about 15-20% 
of patients after ALND and is not dependent on the type of 
RT (WBI or loco-regional RT). Severe impairment of shoulder 
function is rare and not influenced by including regional 
nodes in the RT volume. Awareness of morbidity is important 
to improve future treatment strategies in heavily treated 
breast cancer patients.  
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Purpose/Objective: To investigate the impact in locoregional 
recurrence (LRR) of omission of axillary irradiation (axillary 
level I-II) in patients with ≥7 pathological positive axillary 
lymph nodes (>7pN+) and to identify prognosis factors 
associated in breast cancer patients. 
Materials and Methods: A retrospective database was used to 
identify patients undergoing BCT (breast conserving 
treatment), adjuvant CT (chemotherapy) and radiation 
therapy (RT) from 2000 to 2011. Patients treated with neo-
adjuvant chemotherapy (NCT) were excluded. This study 
analysed 100 patients (34 pN2 and 66 pN3). RT was delivered 
to the chest wall or wall breast and internal lymph nodes 
[internal mammary chain (IMC), supraclavicular, 
infraclavicular and axillary level III]. Disease free survival 
(DFS), metastasis free survival 5(MFS) and overall survival 
were analysed using the Kaplan-Meier method and compared 
using the log-rank test. Cox's proportional hazards regression 
models.  
Results: With a median follow-up time of 63.2 months, 3 
patients relapsed in not irradiated axillary region (1 isolated 
and 2 concomitant with distant metastasis). The median 
removed lymph nodes were 16 and the median lymph node 
ratio (LNR) was 0.8. The five years DFS, MFS and OS was 50%, 
58% and 69.9% respectively. Univariate and multivariate 
analysis showed that triple-negative histologic subtype was 
associated with DFS (HR 3.34 [1.59 ; 7.05] ;p=0.02), MFS (HR 
3.85 [1.59 ;9.29]; p=0.003) and OS (HR 5.77 [2.41 ;13.80]; 
p<0.001). 
Conclusions: The omission of axillary irradiation (level I-II) in 
patient underwent to BCT with an appropriate axillary lymph 
node dissection showed a low rate of regional relapse. Triple-
negative histological subtype in the most important prognosis 
factor in this population. Further prospective studies are 
necessary to assess the clinical impact of the omission of 
axillary irradiation.  
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